Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, shared Akhil Santhosh’s, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, post on X, adding:
“Interesting study (n=89) evaluating losartan for prevention of paclitaxel-induced neuropathy. Losartan significantly reduced ≥Grade 2 neuropathy (33% vs 86%, p<0.001) and delayed onset (73 vs 44 days; HR 0.2, 95% CI 0.11–0.35) compared with standard care. Promising signal.”
Quoting Akhil Santhosh’s post:
“The Effect of Losartan in Preventing Paclitaxel‐Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study – Mahmoud – 2026 – Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy – Wiley Online Library”
Title: The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study
Authors: Aalaa Mahmoud Ahmed Shawqi Mahmoud, Emad Shash, Hayam Ateyya, Farida A. Okasha and Nouran Omar El Said.
Other articles featuring Abi Siva and Akhil Santhosh on OncoDaily.